A Phase 4 interventional study of HX575 recombinant human erythropoietin alfa in Chronic Kidney Disease, sponsored by Sandoz. Completed at 114 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-07-11.
Sponsored by Sandoz (formerly part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic — 1 open to participants now, 1 under way, none of them phase 3. Epoetin Alfa · Renal Insufficiency, Chronic.
Among the 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic, this one has the largest enrollment, is the only one that started in 2008, is one of 7 in phase 4, and was the 10th registered.
3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.
Browse Renal Insufficiency, Chronic studies →1 of the 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic is open now, in 1 country. Recruiting first, the newest first:
Services Hospital, Lahore · Sites in Pakistan
Ages 18–65
By country, each count listing its studies:
Epoetin Alfa: first FDA approval 1989 (EPOGEN/PROCRIT), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2008.
This study's enrollment of 1,695 is above the median of 73 across 2,162 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 157 across the 25 interventional studies. Of the 23 that completed or were terminated, 14 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 25 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sandoz, one of the names counted as Novartis. Under that name alone:
Sandoz is the lead sponsor of 139 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.
28 studies in Renal Insufficiency, Chronic by Novartis: 4 open now, 6 under way, 5 of them phase 3. Of 20 finished, 11 (55%) have results posted.
Among the 28 studies in Renal Insufficiency, Chronic by Novartis, this one is the 2nd largest by enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2008, is one of 3 in phase 4, and was the 2nd registered.
Novartis’s Renal Insufficiency, Chronic studies by the year they started, since 2004.
1 of the studies testing Epoetin Alfa in Renal Insufficiency, Chronic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07755683Services Hospital, LahoreEffect of Daprodustat and Epoetin Alpha on Anemia in Patients Not Undergoing Dialysis | 2027-02-28 |
Add it to your calendar (.ics) → With an account.
Among the 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 28 in Renal Insufficiency, Chronic:
This tab as a report to print or save as PDF → With an account.
Cumulative follow-up with HX575 epoetin alfa to prospectively monitor the incidence of relevant drug-related adverse events and EPO-related lack of efficacy among Chronic Kidney Disease (CKD) subjects receiving HX575 epoetin alfa i.v.
This study was a multi-center, multinational, prospective, single-arm clinical study with a 6-month treatment period. The primary objective was to extend the safety database of patients with CKD who receive i.v. HX575 epoetin alfa treatment and to monitor the adverse event (AE) profile under post-approval conditions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This post-authorization safety study was designed as a multi-center, multinational, prospective, single-arm clinical study with a 6-month HX575 (recombinant human) erythropoietin alfa treatment period. It was planned to include approximately 1,500 patients.
Drug: HX575 recombinant human erythropoietin alfa
HX575 epoetin alfa i.v. will be administered according to the SmPC
Also known as: HX575 epoetin alfa
Drug-related Adverse Events Consisting of Epoetin Alfa-induced Immunogenicity and Resulting Clinical Effects
The incidence of relevant drug-related adverse events consisting of Epoetin alfa-induced immunogenicity and resulting blockade in erythroid maturation (e.g. pure red cell aplasia) and lack of efficacy
Time frame: 6 months
| Milestone | HX575 |
|---|---|
| Started | 1695 |
| Completed | 1393 |
| Not completed | 302 |
| Withdrew: Death | 82 |
| Withdrew: Withdrawal by subject | 44 |
| Withdrew: Adverse event | 36 |
| Withdrew: Renal transplantation | 17 |
| Withdrew: Need for systemic immunosuppressive medi | 8 |
| Withdrew: Non-compliance | 8 |
| Withdrew: Development of uncontrolled hypertension | 5 |
| Withdrew: Moved to other dialysis unit, etc. | 102 |
The incidence of relevant drug-related adverse events consisting of Epoetin alfa-induced immunogenicity and resulting blockade in erythroid maturation (e.g. pure red cell aplasia) and lack of efficacy
| percentage of participants | HX575 |
|---|---|
| Drug-related AEs | 7 (5.9 to 8.3) |
| EPO-related lack of efficacy events | 0.18 (0.04 to 0.52) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| HX575 | 82/1,695 (4.8%) | 456/1,695 (26.9%) | 1,314/1,695 (77.5%) |
| Event | HX575 |
|---|---|
| PneumoniaInfections and infestations | 34/1695 |
| Arteriovenous fistula thrombosisInjury, poisoning and procedural complications | 24/1695 |
| Shunt thrombosisInjury, poisoning and procedural complications | 17/1695 |
| SepsisInfections and infestations | 16/1695 |
| Atrial fibrillationCardiac disorders | 13/1695 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 11/1695 |
| Peripheral arterial occlusive diseaseVascular disorders | 11/1695 |
| Arteriovenous fistula site complicationInjury, poisoning and procedural complications | 11/1695 |
| Cardiac failureCardiac disorders | 11/1695 |
| Cardiac arrestCardiac disorders | 10/1695 |
| Event | HX575 |
|---|---|
| Muscle spasmsMusculoskeletal and connective tissue disorders | 223/1695 |
| HeadacheNervous system disorders | 181/1695 |
| HypertensionVascular disorders | 174/1695 |
| DiarrhoeaGastrointestinal disorders | 161/1695 |
| HypotensionVascular disorders | 145/1695 |
| BronchitisInfections and infestations | 136/1695 |
| Procedural hypotensionInjury, poisoning and procedural complications | 111/1695 |
| NauseaGastrointestinal disorders | 105/1695 |
| VomitingGastrointestinal disorders | 102/1695 |
| NasopharyngitisInfections and infestations | 100/1695 |
| Age, Continuous(years) | HX575 |
|---|---|
| Mean | 61.8 ± 15.4 |
| Sex: Female, Male(Participants) | HX575 |
|---|---|
| Female | 737 |
| Male | 958 |
| Race (NIH/OMB)(Participants) | HX575 |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 9 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 6 |
| White | 1671 |
| More than one race | 0 |
| Unknown or Not Reported | 9 |
| Region of Enrollment(participants) | HX575 |
|---|---|
| Austria | 44 |
| Russian Federation | 29 |
| Romania | 103 |
| Macedonia, The Former Yugoslav Republic of | 143 |
| Ukraine | 204 |
| Poland | 220 |
| Italy | 205 |
| Bulgaria | 45 |
| France | 1 |
| Germany | 701 |
Showing the first 100 of 114 sites across 10 countries. Choose a country and city above to see the rest.
Plan to share: Undecided
The record gives a start of Jul 2008, a primary completion of Mar 2010 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2017, 7 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Epoetin Alfa
Renal Insufficiency, Chronic →